🇺🇸 FDA

Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
642

Quick answer

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TEV-48574

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  2. TEV-48574, Placebo IMP for sc infusion is provided as a liquid solution in the same formulation as TEV-48574, except for the absence of active protein.

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  3. TEV-53408, Placebo to match TEV-53408

    Lacuna Pharma Pty Ltd

    Celiac Disease

    phase 2 small molecule active

    1 trial

  4. TL-895, TL-895

    Lacuna Pharma Pty Ltd

    B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  5. TL-895, TL-895, TL-895, TL-895 matching placebo, TL-895, TL-895

    Lacuna Pharma Pty Ltd

    Indolent Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  6. Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 140 mg hard capsules, Temodal 180 mg hard capsules, Temodal 100 mg hard capsules, Temodal 5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NOX-A12, Temodal 250 mg hard capsules, MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Temodal 20 mg hard capsules, Temodal 250 mg hard capsules, Temodal 180

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 small molecule active

    1 trial

  7. Terbinafin "Moberg Pharma", kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terclara, kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea

    Lacuna Pharma Pty Ltd

    Distal Subungual Onychomycosis

    phase 2 small molecule active

    1 trial

  8. The corresponding placebo solution consists of the 25 nM phosphate buffer solution with 4 μg of vitamin B2 added for colouring purposes only., RBD1016, Vemlidy 25 mg film-coated tablets.

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  9. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  10. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  11. Thiogamma 600 mg Filmtabletten, Benfogamma Forte, 300 mg, tabletki powlekane

    Lacuna Pharma Pty Ltd

    Diabetic sensorimotor polyneuropathy (DSPN)

    phase 2 small molecule active

    1 trial

  12. Tovinontrine, Tovinontrine, Tovinontrine, tovinontrine-matching placebo, immediate-release tablet

    Lacuna Pharma Pty Ltd

    Heart failure (HF) with reduced ejection fraction (HFrEF)

    phase 2 small molecule active

    1 trial

  13. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial

  14. TransCon CNP 3.9 mg CNP-38/vial, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  15. TransCon CNP, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  16. TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  17. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  18. TransCon hGH, TransCon hGH, TransCon CNP

    Lacuna Pharma Pty Ltd

    Children with Achondroplasia

    phase 2 small molecule active

    1 trial

  19. Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  20. VANCOMYCIN , MaaT013

    Lacuna Pharma Pty Ltd

    Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

    phase 2 small molecule active

    1 trial

  21. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  22. VENETOCLAX, VENETOCLAX, SY-1425, VENETOCLAX, AZACITIDINE

    Lacuna Pharma Pty Ltd

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  23. Vehicle to TOP-N53, TOP-N53, Sildenafil Teva 20 mg filmomhulde tabletten

    Lacuna Pharma Pty Ltd

    Digital ulcers in systemic sclerosis

    phase 2 small molecule active

    1 trial

  24. Vi-Siblin S granulat, alli 60 mg hard capsules, Dietary fibre supplement Placebo - Maltodextrin

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial

  25. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 2 small molecule active

    1 trial

  26. Vipoglanstat, The placebo formulation for GS-248 is formulated in a capsule without the active ingredient. Both vipoglanstat capsules and placebo are identical capsules.

    Lacuna Pharma Pty Ltd

    Endometriosis related pain

    phase 2 small molecule active

    1 trial

  27. Vonafexor

    Lacuna Pharma Pty Ltd

    Alport Syndrome

    phase 2 small molecule active

    1 trial

  28. Vonafexor, ROSUVASTATIN , IOHEXOL , Vonafexor

    Lacuna Pharma Pty Ltd

    Impaired renal function and suspected MASH

    phase 2 small molecule active

    1 trial

  29. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial

  30. ZADAXIN® 1,6 mg/ml

    Lacuna Pharma Pty Ltd

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  31. alpha 1H, Placebo product for Alpha1H

    Lacuna Pharma Pty Ltd

    Non-muscle invasive bladder cancer awaiting transurethral surgery

    phase 2 small molecule active

    1 trial

  32. bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  33. non-preserved sterile liquid formulation

    Lacuna Pharma Pty Ltd

    Type 2 diabetes and Obesity

    phase 2 small molecule active

    1 trial

  34. phosphate buffered saline., FX06

    Lacuna Pharma Pty Ltd

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  35. sotatercept, PL1 - Powder for injection

    Lacuna Pharma Pty Ltd

    Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  36. tamuzimod, tamuzimod, tamuzimod, VTX002 placebo film-coated tablets matching VTX002, tamuzimod

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  37. tovinontrine-matching placebo, immediate-release tablet, Tovinontrine

    Lacuna Pharma Pty Ltd

    chronic heart failure

    phase 2 small molecule active

    1 trial

  38. A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  39. A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  40. A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis

    Lacuna Pharma Pty Ltd

    Ulcerative colitis

    phase 1 other active

    1 trial

  41. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS

    Lacuna Pharma Pty Ltd

    alopecia areata

    phase 1 other active

    1 trial

  42. A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults

    Lacuna Pharma Pty Ltd

    Heathy volunteer trial

    phase 1 other active

    1 trial

  43. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  44. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  45. A First-in-Human Study to Test the Safety and Effects of the Investigational Drug IPH4502 in People with Advanced Cancers

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  46. A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

    Lacuna Pharma Pty Ltd

    Urinary tract infections (UTIs)/complicated UTI (cUTI)

    phase 1 other active

    1 trial

  47. A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Nervous System disease

    phase 1 other active

    1 trial

  48. A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

    Lacuna Pharma Pty Ltd

    Non-muscle Invasive Bladder Cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.